Company: BDRX
Filing Date: 2025-05-01
Form Type: DRS
Source: 0001214659-25-006756
Chunk: 153

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-01
Form: DRS
Chunk 153
---
 to “incorporate
by reference” the information we file with the SEC, which means that we can disclose important information to you by referring you
to another document filed separately with the SEC. The information incorporated by reference is an important part of this prospectus.
We incorporate by reference, as of their respective dates of filing, the documents listed below that we have filed with the SEC and any
documents that we file with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this prospectus
and prior to the termination of the offering of securities under this prospectus (except in each case the information contained in such
documents to the extent “furnished” and not “filed”):

| 82 |

We are also incorporating by reference
all subsequent Annual Reports on Form 20-F that we file with the SEC and certain reports on Form 6-K that we furnish to the SEC after
the date of this prospectus (if they state that they are incorporated by reference into this prospectus) prior to the termination of this
offering. In all cases, you should rely on the later information over different information included in this prospectus or any accompanying
prospectus supplement.

Unless expressly
incorporated by reference, nothing in this prospectus shall be deemed to incorporate by reference information furnished to, but not filed
with, the SEC. Copies of all documents incorporated by reference in this prospectus, other than exhibits to those documents unless such
exhibits are specifically incorporated by reference in this prospectus, will be provided at no cost to each person, including any beneficial
owner, who receives a copy of this prospectus on the written or oral request of that person made to:

<div align='center'>Biodexa Pharmaceuticals PLC

1 Caspian Point

Caspian Way

Cardiff, CF10 4DQ, United Kingdom

+44 29 2048 0180</div>

You may also access
these documents on our website, www.biodexapharma.com. The information contained on, or that can be accessed through, our
website is not a part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference.

You should rely
only on information contained in, or incorporated by reference into, this prospectus. We have not authorized anyone to provide you with
information different from that contained in this prospectus or